Exocrine Pancreatic Insufficiency is condition in which pancreas not able to make enough digestive enzymes which is required for the digestion process in intestine. Mainly exocrine pancreas produces three types of enzymes which are amylase, protease and lipase helping in digestion of carbohydrates, proteins, and fat. At normal conditions Lipase breaks triglycerides into fatty acids and monoglycerides. In case of exocrine pancreatic insufficiency when Patients who lack or do not have that much digestive enzyme needed to breakdown food then proper absorption of nutrients will not occur further leading to malnutrition. If timely it is not treated it can result in to other disease like cystic fibrosis, diabetes, even malnutrition. Symptoms of exocrine pancreatic insufficiency observed are bloating, pain in abdomen, weight loss and steatorrhea (oily stool) or watery stool is also observed some times.
For the Diagnosis purpose of exocrine pancreatic insufficiency there are several tests, doctors mostly recommends stool elastase test, pancreatic function test, and blood tests. To know the condition of pancreas diagnosis can be done by CTscan, MRI, and Endoscopic Ultrasound in which inflammation of pancreas can be detected. In case of serious condition for the treatment purpose, doctor treats by (PERT) pancreatic enzyme replacement therapy.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/exocrine-pancreatic-insufficiency-market/
Exocrine Pancreatic Insufficiency Market – Competitive Insight
- In 2024, an oral capsule Adrulipase Alfa developed by recombined technology for the treatment of exocrine pancreatic insufficiency is under phase II clinical trials developed by biotech company First wave Biopharma.
- In 2020 AzurRx Biopharma successfully completed the phase II Clinical trial of MS1819-SD, a yeast-derived recombinant lipase ,an enzyme that breaks up fat molecules for EPI associated with Exocrine pancreatic Insufficiency.
Exocrine Pancreatic Insufficiency Market include –
- AbbVie
- Nestle
- Digestive Care
- AzurRx Biopharma
- Abbott
- Orlando Health,
- Chiesi Farmaceutic
- Allergen Plc
- Janssen pharmaceuticals
- Cilian AG
- Anthera Pharmaceuticals
- Nordmark Arznemittel GmBh
- AstraZeneca
- Johnson & Johnson Private Limited
Exocrine Pancreatic Insufficiency Market – Growth Drivers
The prevalence of exocrine pancreatic insufficiency is increasing due the certain factors like such as increase in the prevalence of diabetes, cystic fibrosis, chronic pancreatitis. Prolonged chronic Pancreatitis directly leads to damage of pancreas tissue which further make deficiency of needed enzymes for digestion. It was written in article published by International journal of Endocrinology that patients 22% of Exocrine pancreatic Insufficiency found in patients who already diagnosed with Diabetes 2 so the leading increase in Diabetes directly increase the occurrence of this Disease. Nowadays market is continuously getting driven by technologies, so the technology which help to treat, prevent and diagnosis the Exocrine pancreatic insufficiency is widely used by people. Awareness about this and Regulatory support, policies which make the increase in use of Exocrine pancreatic Insufficiency Treatment. In COVID 19 ACE 2 Receptor was also responsible for the pancreatic damage in SARS CoV 2 as ACE 2 Receptors are highly found in enterocytes. Diarrhea associated with SARS CoV 2 is major digestive issue faced by People at COVID Period. Cost Reduction of the the treatment also promote the Exocrine pancreatic Insufficiency Market.
Exocrine Pancreatic Insufficiency Market – Restraints
There are many challenging factors which leads to the decline in the market of Exocrine pancreatic Insufficiency like at initial stages High investment is required for the start . start. Many people in rural background are not aware of this Disease they, don’t know what is the cause and how it can be treated so this can be a decline part of Market. People in rural area cannot afford the high cost of treatment which obstruct the market. Regulations and policies are made by government but due to ineffectiveness of the policies make retardation of market. USFDA has advised producers to take proper Authorization before marketing any product which time taking process which limits the market expansion.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/exocrine-pancreatic-insufficiency-market/
Exocrine Pancreatic Insufficiency Market -Opportunities
In coming years more people will be aware of diseases condition which Directlydirectly leads to increase in market. EPI is commonly found in patients having Cystic fibrosis, Diabetes, Chronic Pancreatitis so give prevalence to rising pancreatic disease and making new diagnosis and prevention equipment’ s .As day by day number of diabetic patients are increasing which another key for the companies to work on this disease. Major companies like Pfizer ,Pfizer, Janssen pharmaceutical are focusing on innovation to sustain their position . position. Many started initiatives like PACT CB registry Study and acquisitions for fulfilling the need which not till introduced in market.
Exocrine Pancreatic Insufficiency Market -Geographical Insights
North America is leading market of Exocrine pancreatic Insufficiency having robust vehicle infrastructure ,infrastructure, Government initiatives and Growing environmental awareness is so well which is responsible for the leading Market of EPI. Not only the economic status but also the increasing geriatric population is major reason of more people found as diabetic further to Exocrine Pancreatic Insufficiency .Insufficiency. According to a report published by national center of Drug Abuse Statistics approximately 60% of American has increased alcohol consumption in period of COVID 19 which increased the Market in North America.
Europe is another key market of Exocrineexocrine pancreatic Insufficiency which mainly focusing on the expansion of charging infrastructure and government strong support to accelerate market development. Asia Pacific regions have potential in growth of this Market ,Market , Particularly china which having technology benefits along with the government support.
Exocrine Pancreatic Insufficiency Market- Key Developments
- In April 2022, leading company called Alcresta Therapeutics focused on developing and commercializing enzyme-based products and their main product was RELIZORB
- In February 2022 University of Miami surveyed and tried PERT (pancreatic enzyme replacement Therapy) in patients